
YMAB
Healthcare · Biotechnology · $391.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2025
EPS trend, 90 days to now · +20.1% over 90 days · 30-day revisions 4 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | Time not confirmed | -0.22 | 0.00 | +100.0% |
| Aug 8, 2025 | Time not confirmed | -0.26 | -0.07 | +73.1% |
| May 5, 2025 | Before the open | -0.14 | -0.12 | +14.3% |
| Feb 26, 2025 | After the close | -0.13 | -0.15 | -13.6% |
| Nov 8, 2024 | Before the open | -0.15 | -0.16 | -6.7% |
| Aug 12, 2024 | Before the open | -0.13 | -0.21 | -61.5% |
| May 7, 2024 | After the close | -0.14 | -0.15 | -7.1% |
| Feb 29, 2024 | After the close | -0.20 | -0.02 | +90.0% |
| Nov 13, 2023 | After the close | -0.19 | -0.18 | +5.3% |
| Aug 10, 2023 | After the close | -0.24 | -0.14 | +41.7% |
| May 8, 2023 | After the close | -0.32 | -0.15 | +53.1% |
| Mar 30, 2023 | After the close | -0.46 | 0.03 | +106.5% |
| Nov 7, 2022 | After the close | -0.71 |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in…
| -0.63 |
| +11.3% |
| Aug 8, 2022 | After the close | -0.67 | -0.94 | -40.3% |
| May 9, 2022 | After the close | -0.72 | -0.64 | +11.1% |
| Feb 24, 2022 | After the close | -0.70 | -0.85 | -21.4% |
| Nov 4, 2021 | After the close | -0.60 | -0.66 | -10.0% |
| Aug 5, 2021 | After the close | -0.67 | -0.53 | +20.9% |
| May 6, 2021 | After the close | 0.19 | -0.68 | -457.9% |
| Feb 25, 2021 | After the close | -0.51 | -0.48 | +5.9% |
| Nov 5, 2020 | After the close | -0.78 | -0.82 | -5.1% |
| Aug 6, 2020 | After the close | -0.68 | -1.01 | -48.5% |
| May 7, 2020 | After the close | -0.62 | -0.66 | -6.5% |
| Mar 12, 2020 | After the close | -0.67 | -0.60 | +10.4% |
| Nov 13, 2019 | After the close | -0.55 | -0.70 | -27.3% |
| Aug 14, 2019 | After the close | -0.49 | -0.53 | -8.2% |
| May 10, 2019 | After the close | -0.41 | -0.47 | -14.6% |
| Mar 22, 2019 | After the close | -0.31 | -0.42 | -35.5% |
| Nov 13, 2018 | Before the open | -0.36 | -0.42 | -16.7% |
| Sep 24, 2018 | After the close | 0.00 | -0.45 | — |